Ritobegron | CAS#255734-04-4 | β3-adrenoceptor agonist

MedKoo Cat#: 461350 | Name: Ritobegron

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ritobegron, also known as KUC 7322, is a selective β3-adrenoceptor agonist and the prodrug of the active compound, KUC-7322.

Chemical Structure

Ritobegron

CAS#255734-04-4

Theoretical Analysis

MedKoo Cat#: 461350

Name: Ritobegron

CAS#: 255734-04-4

Chemical Formula: C21H27NO5

Exact Mass: 373.1889

Molecular Weight: 373.44

Elemental Analysis: C, 67.54; H, 7.29; N, 3.75; O, 21.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Ritobegron; KUC 7322; KUC-7322; KUC7322;

IUPAC/Chemical Name

2-(4-(2-(((1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)amino)ethyl)-2,5-dimethylphenoxy)acetic acid

InChi Key

VMMYRRFPMAGXNP-BTYIYWSLSA-N

InChi Code

InChI=1S/C21H27NO5/c1-13-11-19(27-12-20(24)25)14(2)10-17(13)8-9-22-15(3)21(26)16-4-6-18(23)7-5-16/h4-7,10-11,15,21-23,26H,8-9,12H2,1-3H3,(H,24,25)/t15-,21-/m0/s1

SMILES Code

O=C(O)COC1=CC(C)=C(CCN[C@@H](C)[C@H](O)C2=CC=C(O)C=C2)C=C1C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 373.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Abe Y, Ota E, Harada H, Kanbe H, Kojima Y, Kanazawa T, Endo T, Murakami M, Kobayashi M. Species differences in the metabolism of ritobegron in vitro and assessment of potential interactions with transporters and cytochrome P450 enzymes. Pharmazie. 2015 Jan;70(1):38-46. PubMed PMID: 25975097. 2: Abe Y, Ota E, Endo T, Murakami M, Kobayashi M. Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. Pharmazie. 2014 Dec;69(12):881-8. PubMed PMID: 25951660. 3: Maruyama I, Yonekubo S, Tatemichi S, Maruyama K, Hoyano Y, Yamazaki Y, Kusama H. Effects of ritobegron (KUC-7483), a novel β3-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine. J Smooth Muscle Res. 2012;48(5-6):115-24. PubMed PMID: 23538508. 4: Abe Y, Nakano Y, Kanazawa T, Furihata T, Endo T, Kobayashi M. Investigation of Drug-Drug Interactions Between Ritobegron, a Selective β3 -Adrenoceptor Agonist, With Probenecid in Healthy Men. Clin Pharmacol Drug Dev. 2016 May;5(3):201-7. doi: 10.1002/cpdd.212. Epub 2015 Sep 29. PubMed PMID: 27163499. 5: Maruyama I, Tatemichi S, Goi Y, Maruyama K, Hoyano Y, Yamazaki Y, Kusama H. Effects of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther. 2012 Jul;342(1):163-8. doi: 10.1124/jpet.112.191783. Epub 2012 Apr 16. PubMed PMID: 22511202. 6: Maruyama I, Goi Y, Tatemichi S, Maruyama K, Hoyano Y, Yamazaki Y, Kusama H. Bladder selectivity of the novel β₃-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat. Naunyn Schmiedebergs Arch Pharmacol. 2012 Aug;385(8):845-52. doi: 10.1007/s00210-012-0755-x. Epub 2012 May 3. PubMed PMID: 22552730. 7: Thiagamoorthy G, Cardozo L, Robinson D. Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother. 2016 Jul;17(10):1317-25. doi: 10.1080/14656566.2016.1186645. Epub 2016 Jun 2. Review. PubMed PMID: 27253972. 8: Thiagamoorthy G, Giarenis I, Cardozo L. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome. Expert Opin Investig Drugs. 2015;24(10):1299-306. doi: 10.1517/13543784.2015.1076390. Epub 2015 Aug 14. Review. PubMed PMID: 26292923. 9: Michel MC, Korstanje C. β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. Pharmacol Ther. 2016 Mar;159:66-82. doi: 10.1016/j.pharmthera.2016.01.007. Epub 2016 Jan 22. Review. PubMed PMID: 26808167. 10: Burden H, Abrams P. Urinary incontinence in men: current and developing therapy options. Expert Opin Pharmacother. 2016;17(5):715-26. doi: 10.1517/14656566.2016.1145662. Epub 2016 Mar 3. Review. PubMed PMID: 26800277. 11: Igawa Y, Michel MC. Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):177-83. doi: 10.1007/s00210-012-0824-1. Epub 2012 Dec 21. PubMed PMID: 23263450. 12: Igawa Y, Schneider T, Yamazaki Y, Tatemichi S, Homma Y, Nishizawa O, Michel MC. Functional investigation of β-adrenoceptors in human isolated detrusor focusing on the novel selective β3-adrenoceptor agonist KUC-7322. Naunyn Schmiedebergs Arch Pharmacol. 2012 Aug;385(8):759-67. doi: 10.1007/s00210-012-0763-x. Epub 2012 May 29. PubMed PMID: 22644105.